When the neutrophil count is too low, it is known as neutropenia. Typically, a low neutrophil count (neutropenia) results in ...

X4 Pharmaceuticals announced that its Phase 3 4WARD trial for chronic neutropenia is now active at around 90% of targeted sites, with expected full enrollment by Q3 or Q4 of 2025 and top-line data ...

X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...

Neutropenia in individuals with a congenital defect or patients with cancer who are undergoing chemotherapy is generally treated with granulocyte colony-stimulating factor (G-CSF) to restore ...

Chemotherapy-induced neutropenia is a major risk factor for infection-related morbidity and mortality and an important dose-limiting toxicity in cancer treatment. The incidence of severe ...

PRT2527 demonstrated a manageable safety profile with most common side effects being neutropenia (48%) and nausea (33%). No treatment-emergent adverse events (TEAEs) led to discontinuation in the ...